talquetamab
janssen
['multiplemyeloma', 'monumental-1', 'janssen']
for us #hcps at #eha2023, see dr. cyrille touzeau present pivotal phase 2 results from the phase 1/2 monumental-1 study investigating a gprc5d bispecific antibody in patients with relapsed/refractory #multiplemyeloma. 
Dedicated to sharing Janssen Oncology scientific communications for US HCPs. Account run by Janssen Global Services LLC. Review our Guidelines: https://t.co/uieWByQjn3.